Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients

    NEXT STORY
    Cell Analysis Global Market – Forecast to 2027
    PREV STORY
    Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    American Gene Technologies Inc. Appoints Julia R. Brown to its Board of Directors

    ROCKVILLE, Md., Sept. 11, 2017 (GLOBE NEWSWIRE) -- American Gene Technologies International Inc. (AGT), ...

    author_avatar
    NASDAQ Market News

    Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

    author_avatar
    NASDAQ Market News

    Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US

    Today PledPharma (publ) announces that the company has received a positive conclusion of the ...

    author_avatar
    NASDAQ Market News